Recently, we identified and developed a novel uPAR targeted monoclonal antibody that demonstrates robust antitumor effects in a number of different animal tumor models but does not block the binding of uPA to uPAR [22], [26]–[28]. The gene discussed is PLAU; the disease is neoplasm.